<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30967" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Vancomycin-Resistant Enterococci</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Levitus</surname>
            <given-names>Matthew</given-names>
          </name>
          <aff>Hofstra Northwell</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rewane</surname>
            <given-names>Ayesan</given-names>
          </name>
          <aff>Rush University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Perera</surname>
            <given-names>Thomas B.</given-names>
          </name>
          <aff>Hofstra Northwell</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Matthew Levitus declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ayesan Rewane declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Thomas Perera declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30967.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Antimicrobial resistance is becoming an increasingly common clinical dilemma for medical providers. In particular, vancomycin-resistant Enterococcus (VRE) is challenging to manage. Enterococci are facultative anaerobic gram-positive cocci that are normally commensal organisms of the human gastrointestinal tract. However, they can cause a variety of infections. This activity reviews the development of vancomycin-resistant Enterococcus and its epidemiology and presentation, and highlights the role of the interprofessional team in the management of affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of vancomycin-resistant Enterococcus.</p></list-item><list-item><p>Review the presentation of vancomycin-resistant Enterococcus.</p></list-item><list-item><p>Summarize the treatment considerations for vancomycin-resistant Enterococcus.</p></list-item><list-item><p>Explain interprofessional team strategies for improving care coordination and outcomes in patients with vancomycin-resistant Enterococcus.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30967&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30967">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30967.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Antimicrobial resistance is becoming an increasingly common clinical dilemma for medical providers. In particular, vancomycin-resistant <italic toggle="yes">Enterococcus</italic> (VRE) has become a challenge to manage in the hospital setting. Enterococci are facultative anaerobic gram-positive cocci in pairs/chains that live in the gastrointestinal (GI) tract and ordinarily function commensally with humans. However, they can cause a variety of infections, most commonly urinary tract infection (UTI), intraabdominal infection, bacteremia, or endocarditis. Rarely, they can cause meningitis, osteomyelitis, septic arthritis, or pneumonia. Additionally, vancomycin-resistant <italic toggle="yes">Enterococcus</italic> often exists as a colonizing organism that does not always contribute to infection, making it more difficult to determine when and how to treat these infections. Despite these difficulties, infection of vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus</italic>&#x000a0;has been shown to increase both cost and mortality when compared to vancomycin-susceptible isolates. With increasing rates of vancomycin resistance among <italic toggle="yes">Enterococcus</italic> isolates, good stewardship combined with aggressive treatment with targeted antibiotics is necessary to treat this frequently encountered infection.<xref ref-type="bibr" rid="article-30967.r1">[1]</xref><xref ref-type="bibr" rid="article-30967.r2">[2]</xref><xref ref-type="bibr" rid="article-30967.r3">[3]</xref></p>
      </sec>
      <sec id="article-30967.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Enterococci have developed a variety of mechanisms of resistance to several antibiotics like aminoglycosides,<italic toggle="yes"> B</italic>-lactams, tetracyclines, quinolones, and vancomycin (glycopeptide). Intrinsically, they have penicillin-binding proteins with low-affinity to beta-lactams, can produce beta-lactamases, and have decreased cellular permeability to several. Specifically, vancomycin-resistant <italic toggle="yes">Enterococcus</italic> resistance is due to the changes in the formation of peptidoglycan that makes up the bacterial cell wall. Normally, vancomycin binds to the D-Ala-D-Ala terminus of the protein precursors to peptidoglycan. Resistance develops as this terminus is changed to D-Ala-D-lactate so that vancomycin binds with less affinity. This is coded by genotypes identified alphabetically as <italic toggle="yes">VanA</italic> to <italic toggle="yes">VanG</italic>. Of these, the plasmid-based <italic toggle="yes">VanA</italic> and <italic toggle="yes">VanB</italic> genotypes are by far the most common, followed distantly in prevalence by the chromosomal phenotypes <italic toggle="yes">VanD</italic> and <italic toggle="yes">VanC</italic>&#x000a0;respectively. VRE has slightly different resistance formation with Aminoglycosides, all except for Streptomycin, the formation of resistance is&#x000a0;mainly due to&#x000a0;inactivating enzyme 2"-phosphotransferase-6&#x02032;-acetyltransferase. Streptomycin resistance on the other is&#x000a0;through the production of&#x000a0;streptomycin adenyltransferase.<xref ref-type="bibr" rid="article-30967.r4">[4]</xref><xref ref-type="bibr" rid="article-30967.r5">[5]</xref><xref ref-type="bibr" rid="article-30967.r6">[6]</xref><xref ref-type="bibr" rid="article-30967.r7">[7]</xref></p>
      </sec>
      <sec id="article-30967.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Beginning in the 1980s, isolates of vancomycin-resistant Enterococcus were demonstrated in Europe, likely arising due to the use of the glycopeptide antibiotic avoparcin in livestock to promote growth. Development in the United States was probably due to increasing use of vancomycin in the clinical setting. Throughout the 1990s and 2000s, multiple epidemics have plagued hospitals due to person-to-person transmission. After fecal shedding, vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus&#x000a0;</italic>is found on the skin and spreads via exposed or contaminated surfaces.&#x000a0;</p>
        <p>According to the National Healthcare Safety Network, enterococci species ranked as the second overall healthcare-associated infection between 2011 and 2014. In particular, <italic toggle="yes">E. Faecalis</italic> was a cause in 7.4% of cases. Furthermore, Enterococci species were found to be the number one isolate for central line-associated bloodstream infections (CLABSI), number three for catheter-associated urinary tract infection (CAUTI), number eleven for ventilator-associated pneumonia (VAP) and number two for surgical site infections (SSI). While the majority of Enterococcus isolates are <italic toggle="yes">E. faecalis</italic>, the majority of vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus&#x000a0;</italic>isolates are <italic toggle="yes">E. faecium</italic>. From 2011 to 2014 the resistance of <italic toggle="yes">E. faecium</italic> to vancomycin was as high as 83.8&#x000a0;% of isolates for CLABSI and 86.2&#x000a0;% for CAUTI. In 2013 the CDC categorized vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus&#x000a0;</italic>as a &#x0201c;serious threat,&#x0201d; suggesting the need for increased monitoring and prevention activities.&#x000a0;</p>
        <p>There are many risk factors for vancomycin-resistant <italic toggle="yes">Enterococcus </italic>colonization and subsequent infections. The most commonly observed risk factor is previous antimicrobial therapy. This mechanism&#x000a0;likely&#x000a0;is due to alteration in bowel flora. Furthermore, patients at increased risk are those with severe underlying illnesses or immunosuppression. This also includes patients with a long hospital stay, admission to long-term care facilities, extended use of antibiotics, and proximity to other patients with vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus</italic>.<xref ref-type="bibr" rid="article-30967.r8">[8]</xref><xref ref-type="bibr" rid="article-30967.r9">[9]</xref></p>
      </sec>
      <sec id="article-30967.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with an underlying vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus&#x000a0;</italic>infection will present with a variety of history and physical exam findings dependent on the clinical manifestations as described below. Specifically, the focus should be placed on using the patient&#x02019;s medical history and physical exam to elucidate the source of infection.&#x000a0;</p>
        <p>
<bold>Clinical Manifestations</bold>
</p>
        <p>Enterococcus can cause a wide range of clinical diseases. The most common clinical presentation is bacteriuria, though it is becoming increasingly clear that many of these cases are due to colonization rather than infection. Other frequent causes of infection are bacteremia without endocarditis, followed by endocarditis.&#x000a0;</p>
        <p>
<bold>
<italic toggle="yes">Urinary tract infection</italic>
</bold>
</p>
        <p>Enterococcus is frequently cited as one of the three most likely etiologies of both uncomplicated and complicated UTI, especially healthcare-associated UTIs. Of these, the vast majority is <italic toggle="yes">E. faecalis</italic>, though the majority of vancomycin-resistant isolates are <italic toggle="yes">E. faecium</italic>. It is usually associated with indwelling urinary catheters and instrumentation. The severity of the disease can range from uncomplicated cystitis to complicated cystitis to pyelonephritis, perinephric abscess, or prostatitis. There is an increasing awareness that many reported &#x0201c;urinary tract infections&#x0201d; are, in fact, colonization. Asymptomatic pyuria and bacteriuria should not be treated unless the patient is exhibiting signs and/or symptoms of a UTI or sepsis.</p>
        <p>
<italic toggle="yes">
<bold>Intra-abdominal and pelvic infections</bold>
</italic>
</p>
        <p>As commensals, vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus&#x000a0;</italic>is commonly isolated from intra-abdominal and pelvic infections. The usual&#x000a0;infections include abscesses, wounds, or peritonitis. Often they are part of a polymicrobial infection with other gram-negative or anaerobic organisms. Nonetheless, intra-abdominal and pelvic abscesses are commonly associated with enterococcal bacteremia prompting antibiotic coverage of E<italic toggle="yes">nterococcus</italic>.</p>
        <p>
<bold>
<italic toggle="yes">Bacteremia</italic>
</bold>
</p>
        <p>Bacteremia is a common and life-threatening manifestation of vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus</italic>. Nosocomial bacteremic infections are regularly acquired due to intravascular catheters or urinary catheters. In the community, bacteremia is commonly due to translocation from the GI and genitourinary (GU) tract. <italic toggle="yes">E. faecium</italic> in the bloodstream is associated with increased mortality likely due to the higher levels of resistance.&#x000a0;</p>
        <p>
<italic toggle="yes">
<bold>Infective endocarditis</bold>
</italic>
</p>
        <p>Enterococci are the second most common cause of infective endocarditis. Common sources are central lines, GI or GU tracts after manipulation, damaged mitral or aortic valve infections, or liver transplantation. Community-acquired endocarditis can occur, and it is usually due to <italic toggle="yes">E. faecalis</italic> in patients with no risk factors. Clinically, they present subacutely with fevers and constitutional symptoms. Typical signs of infection include fevers or a new murmur. Typical stigmata of endocarditis such as petechiae, Osler nodes, and Roth spots are rare and, as with other etiologies, typically occur with subacute infection rather than acute infection.&#x000a0;</p>
        <p>
<bold>
<italic toggle="yes">Uncommon sites of infection</italic>
</bold>
</p>
        <p>Vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus&#x000a0;</italic>is an uncommon cause of central nervous system (CNS) infections. However, when it does occur, the majority are caused by <italic toggle="yes">E. faecium</italic> over <italic toggle="yes">E. faecalis</italic>. Infection&#x000a0;usually&#x000a0;is associated with neurosurgical intervention such as shunts. Like most CNS infections, common presentations include altered mental status and fevers. Vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus&#x000a0;</italic>also&#x000a0;is found in skin infections as a part of a microbial infection. They can be found in decubitis ulcers, osteomyelitis, and soft tissue abscesses. Finally, pneumonia secondary to enterococci is very rare. When it does occur,&#x000a0;it is usually seen as VAP in severely debilitated and immunocompromised patients who have received broad-spectrum antibiotics in the past.<xref ref-type="bibr" rid="article-30967.r7">[7]</xref></p>
      </sec>
      <sec id="article-30967.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Workup for vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus&#x000a0;</italic>will begin with the determination that the patient has an underlying infectious disease process. Next, each potential source of infection needs to be evaluated. Specimens from the potential source should be sent for routine cultures&#x000a0;before administration of empiric antibiotics to determine the exact species and drug susceptibilities. Sensitivities for fosfomycin, daptomycin, nitrofurantoin, and chloramphenicol are not standard in all laboratories and should be added as clinically appropriate.<xref ref-type="bibr" rid="article-30967.r10">[10]</xref><xref ref-type="bibr" rid="article-30967.r11">[11]</xref></p>
      </sec>
      <sec id="article-30967.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Antibiotic therapy for the treatment of vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus&#x000a0;</italic>depends on the type of&#x000a0;infection and drug susceptibility of the organism or organisms involved. In monomicrobial infections, the antibiotic choice should be tailored to tissue for penetration, culture, and local resistance patterns. Moreover, treatment can be controversial as vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus&#x000a0;</italic>often&#x000a0;can be found as a colonizer in polymicrobial infections. Initiation of vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus&#x000a0;</italic>coverage should be initiated based on clinical suspicion or failure of prior antibiotic regimens.&#x000a0;<xref ref-type="bibr" rid="article-30967.r12">[12]</xref><xref ref-type="bibr" rid="article-30967.r13">[13]</xref><xref ref-type="bibr" rid="article-30967.r14">[14]</xref></p>
        <p>The vast majority of enterococcal infections are due to <italic toggle="yes">E. faecalis</italic>. <italic toggle="yes">E. faecalis</italic> tends to be susceptible to beta-lactams and aminoglycosides. Vancomycin resistance is more frequent in undifferentiated <italic toggle="yes">E. faecalis</italic> than resistance to aminopenicillins, stressing that beta-lactams should remain the first choice in most infections&#x000a0;before culture data. Conversely, most strains of <italic toggle="yes">E. faecium</italic> are highly resistant to beta-lactams and aminoglycosides. In general, if vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus&#x000a0;</italic>is highly resistant to other antimicrobial therapies; the two major treatments are linezolid and daptomycin. A meta-analysis of these two therapies has shown that the overall mortality, clinical cure, microbiological cure, and relapse rate were not significantly&#x000a0;different. Importantly, the most common genotypic causes of vancomycin resistance are <italic toggle="yes">VanA</italic> and <italic toggle="yes">VanB</italic> which are inducible resistance genes. As a result, patients with initially vancomycin sensitive isolates that do not respond to treatment should be re-cultured.</p>
        <p>If vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus&#x000a0;</italic>is isolated and highly susceptible, therapy should be narrowed. For UTIs, monotherapy with high dose ampicillin, 18 to 30 g/day intravenous (IV), should be started. If the UTI is uncomplicated but resistant to ampicillin, then nitrofurantoin 100 mg per os (PO) twice a day or fosfomycin 3g PO single dose are the preferred agents. However, it is important to note that UTIs could be secondary to colonization and removal of the catheter could be therapeutic. For bacteremia, monotherapy with ampicillin&#x000a0;often&#x000a0;can be used as&#x000a0;well. However, this does not provide bactericidal activity, so an aminoglycoside such as gentamycin can usually be added. Ampicillin with ceftriaxone is an alternative regimen as it has similar efficacy to ampicillin and gentamycin but is less nephrotoxic.&#x000a0;</p>
        <p>If sensitivities are not available, or for high levels of resistance to beta-lactams or aminoglycosides, linezolid, 600 mg PO or IV twice a day, can be used. A synthetic oxazolidinone antibiotic, this is a bacteriostatic drug that binds to the ribosome, preventing peptide bond formation. For endocarditis, linezolid has been shown to be&#x000a0;an effective first-line medication, although it is a bacteriostatic drug. Adverse effects, especially after prolonged use, include thrombocytopenia, anemia, peripheral neuropathy, and risk of inducing serotonin syndrome. Alternatives should be considered with patients who regularly take serotonergic medications.</p>
        <p>Another alternative is an off-label use of high dose daptomycin 8 to 12 mg/kg IV (with renal adjustment) once a day. A lipopeptide antibiotic, it is bactericidal and causes cell membrane depolarization. Importantly, if patients are persistently bacteremic or the minimum inhibitory concentration is high for daptomycin, then combination therapy with ampicillin or ceftaroline can be used. Patients should be evaluated for myopathy, and weekly creatine kinase levels should be obtained. Furthermore, daptomycin is not effective on pulmonary infections as surfactant inactivates it, but this is rarely a concern with vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus&#x000a0;</italic>because enterococcal pneumonia is exceedingly rare.</p>
        <p>Tigecycline, a glycylcycline antibiotic, can be used for patients who are&#x000a0;intolerant to other agents. It&#x000a0;also&#x000a0;can be used if other infections are present with the vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus&#x000a0;</italic>as it has good coverage against gram positives, some gram negatives, and anaerobes. Although it is off-label, it is specifically considered a preferred agent for polymicrobial intraabdominal infections. It should not be used for vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus&#x000a0;</italic>bacteremia as it distributes primarily to tissues and achieves low serum concentrations. Typical dosing is 100 mg IV once followed by 50 mg IV twice a day. Patients should be monitored for major adverse effects such as nausea and vomiting.</p>
        <p>Chloramphenicol, at 50 to 100 mg/kg/day divided into doses every 6 hours (4 g/day max dose), has been used successfully to treat vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus&#x000a0;</italic>bacteremia for many years and has excellent tissue penetration, including the CNS. Due to its high incidence of toxicity and adverse effects, such as aplastic anemia or bone marrow suppression, it should not be used as a first-line agent when other options are available and should generally&#x000a0;be initiated in consultation with an infectious-disease specialist. It remains an option in resource-poor environments where modern drugs may not be available.<xref ref-type="bibr" rid="article-30967.r7">[7]</xref><xref ref-type="bibr" rid="article-30967.r15">[15]</xref><xref ref-type="bibr" rid="article-30967.r16">[16]</xref><xref ref-type="bibr" rid="article-30967.r7">[7]</xref></p>
      </sec>
      <sec id="article-30967.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Bacterial sepsis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hospital-acquired &#x000a0;infections</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Infective endocarditis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Peritonitis and abdominal sepsis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pyogenic hepatic abscesses</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Septic arthritis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Uti and cystitis in females</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Uti in males</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Wound infection</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30967.s9" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Endocarditis</p>
          </list-item>
          <list-item>
            <p>Colitis</p>
          </list-item>
          <list-item>
            <p>Osteomyelitis</p>
          </list-item>
          <list-item>
            <p>Sepsis</p>
          </list-item>
          <list-item>
            <p>Pneumonia</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30967.s10" sec-type="Consultations">
        <title>Consultations</title>
        <p>Infectious disease consultant</p>
      </sec>
      <sec id="article-30967.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <list list-type="bullet">
          <list-item>
            <p>Hand washing</p>
          </list-item>
          <list-item>
            <p>Good personal hygiene</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30967.s12" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>The primary transmission of vancomycin-resistant&#x000a0;<italic toggle="yes">Enterococcus&#x000a0;</italic>in the hospital setting is through the hands of healthcare providers. Enterococcus can persist&#x000a0;on&#x000a0;hands&#x000a0;for as long as 60 minutes after inoculation&#x000a0;and as long as four months on inanimate surfaces. Basic infection control prevention practices such as hand hygiene can help. This includes washing hands with soap and water or using alcohol-based hand rubs before and after patient encounters. Contact precautions such as wearing gowns and gloves also decrease transmission. In addition, infection control measures such as active surveillance cultures for high-risk patients, patient isolation, and terminal cleaning of rooms are effective.</p>
      </sec>
      <sec id="article-30967.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>While the epidemiology of VRE is not fully known, it is well known that&#x000a0;patients in the ICU are at a very high risk for VRE colonization and infection. There are reports that VRE can be transmitted&#x000a0;by direct patient contact, touching of contaminated surfaces/equipment or through hand transfer after contact with the affected patient. In almost every&#x000a0;hospital in the US, VRE has become a serious problem. In response to this epidemic, almost every hospital now has an infectious disease committee that oversees the use of antibiotics and audits procedures at the bedside for sterility. It is here that the role of the infectious disease nurse and pharmacist is vital. The current recommendations are to 1) only use vancomycin when absolutely&#x000a0;needed, and permission must be&#x000a0;obtained from the board-certified infectious disease pharmacist and clinician infectious disease specialist 2) educate all healthcare workers about VRE 3) implement infection control measures including hand washing, gloves, and gowns when coming into contact with patients who have VRE and 4)&#x000a0;maintain a clean working environment with strict aseptic control. There is evidence to support the use of an interprofessional approach to prevent nosocomial spread of VRE. Many hospitals have now enforced the use of contact isolation and regular surveillance cultures.&#x000a0;<xref ref-type="bibr" rid="article-30967.r17">[17]</xref><xref ref-type="bibr" rid="article-30967.r18">[18]</xref><xref ref-type="bibr" rid="article-30967.r19">[19]</xref>(Level V)</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>Despite the proactive measures, VRE continues to be a problem in many hospitals. Short-term data show that the key to preventing VRE is the cautious use of the antibiotics and remaining compliant with infection control measures, especially in high-risk patients.<xref ref-type="bibr" rid="article-30967.r20">[20]</xref><xref ref-type="bibr" rid="article-30967.r21">[21]</xref> (Level 5)</p>
      </sec>
      <sec id="article-30967.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30967&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30967">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/vancomycin-resistant-enterococci/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30967">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30967/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30967">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30967.s15">
        <title>References</title>
        <ref id="article-30967.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vehreschild</surname>
                <given-names>MJGT</given-names>
              </name>
              <name>
                <surname>Haverkamp</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Biehl</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Lemmen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>F&#x000e4;tkenheuer</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Vancomycin-resistant enterococci (VRE): a reason to isolate?</article-title>
            <source>Infection</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-11</page-range>
            <pub-id pub-id-type="pmid">30178076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30967.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kampmeier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kossow</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clausen</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Knaack</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ertmer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gottschalk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Freise</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mellmann</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Hospital acquired vancomycin resistant enterococci in surgical intensive care patients - a prospective longitudinal study.</article-title>
            <source>Antimicrob Resist Infect Control</source>
            <year>2018</year>
            <volume>7</volume>
            <fpage>103</fpage>
            <pub-id pub-id-type="pmid">30155243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30967.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hussain</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Sattar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>In vitro efficacy of linezolid against vancomycin resistant Enterococci.</article-title>
            <source>Pak J Pharm Sci</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>1853</fpage>
            <page-range>1853-1857</page-range>
            <pub-id pub-id-type="pmid">30150180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30967.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rutala</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Kanamori</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gergen</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Knelson</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Sickbert-Bennett</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Sexton</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>DJ</given-names>
              </name>
              <collab>and the CDC Prevention Epicenters Program</collab>
            </person-group>
            <article-title>Enhanced disinfection leads to reduction of microbial contamination and a decrease in patient colonization and infection.</article-title>
            <source>Infect Control Hosp Epidemiol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>39</volume>
            <issue>9</issue>
            <fpage>1118</fpage>
            <page-range>1118-1121</page-range>
            <pub-id pub-id-type="pmid">30060770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30967.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wassilew</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Seth-Smith</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Rolli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fietze</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Casanova</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>F&#x000fc;hrer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Egli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marschall</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Buetti</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Outbreak of vancomycin-resistant <italic>Enterococcus faecium</italic> clone ST796, Switzerland, December 2017 to April 2018.</article-title>
            <source>Euro Surveill</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>23</volume>
            <issue>29</issue>
            <pub-id pub-id-type="pmid">30043725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30967.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kreidl</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mayr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hinterberger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Berktold</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knabl</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Posch</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Eschertzhuber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Obwegeser</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lass-Fl&#x000f6;rl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Orth-H&#x000f6;ller</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Outbreak report: a nosocomial outbreak of vancomycin resistant <italic>enterococci</italic> in a solid organ transplant unit.</article-title>
            <source>Antimicrob Resist Infect Control</source>
            <year>2018</year>
            <volume>7</volume>
            <fpage>86</fpage>
            <pub-id pub-id-type="pmid">30034798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30967.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cetinkaya</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mayhall</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Vancomycin-resistant enterococci.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>686</fpage>
            <page-range>686-707</page-range>
            <pub-id pub-id-type="pmid">11023964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30967.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coombs</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>Antimicrobial-resistant CC17 Enterococcus faecium: The past, the present and the future.</article-title>
            <source>J Glob Antimicrob Resist</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>16</volume>
            <fpage>36</fpage>
            <page-range>36-47</page-range>
            <pub-id pub-id-type="pmid">30149193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30967.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDermott</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Skally</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>O'Rourke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Humphreys</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fitzgerald-Hughes</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Near-patient environmental contamination of an intensive care unit with Vancomycin-resistant Enterococci (VRE) and Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae (ESBL-E) before and after the introduction of chlorhexidine bathing for patients.</article-title>
            <source>Infect Control Hosp Epidemiol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>39</volume>
            <issue>9</issue>
            <fpage>1131</fpage>
            <page-range>1131-1132</page-range>
            <pub-id pub-id-type="pmid">29950192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30967.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozbak</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>A novel high-resolution melting analysis approach for rapid detection of vancomycin-resistant enterococci.</article-title>
            <source>Ann Saudi Med</source>
            <year>2018</year>
            <season>May-Jun</season>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>200</fpage>
            <page-range>200-207</page-range>
            <pub-id pub-id-type="pmid">29848938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30967.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shokoohizadeh</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ekrami</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Labibzadeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Alavi</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Antimicrobial resistance patterns and virulence factors of enterococci isolates in hospitalized burn patients.</article-title>
            <source>BMC Res Notes</source>
            <year>2018</year>
            <month>Jan</month>
            <day>02</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">29291749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30967.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Habboush</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Guzman</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <chapter-title>Antibiotic Resistance</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30020649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30967.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lund</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Holzknecht</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Justesen</surname>
                <given-names>US</given-names>
              </name>
            </person-group>
            <article-title>[Treatment of vancomycin-resistant enterococcal infections].</article-title>
            <source>Ugeskr Laeger</source>
            <year>2018</year>
            <month>Apr</month>
            <day>16</day>
            <volume>180</volume>
            <issue>16</issue>
            <pub-id pub-id-type="pmid">29690991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30967.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yadav</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Thakuria</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Madan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Agwan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pandey</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Linezolid and Vancomycin Resistant Enterococci: A Therapeutic Problem.</article-title>
            <source>J Clin Diagn Res</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>11</volume>
            <issue>8</issue>
            <fpage>GC07</fpage>
            <page-range>GC07-GC11</page-range>
            <pub-id pub-id-type="pmid">28969155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30967.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Driscoll</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Crank</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management.</article-title>
            <source>Infect Drug Resist</source>
            <year>2015</year>
            <volume>8</volume>
            <fpage>217</fpage>
            <page-range>217-30</page-range>
            <pub-id pub-id-type="pmid">26244026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30967.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raza</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ullah</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Mehmood</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Andleeb</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Vancomycin resistant Enterococci: A brief review.</article-title>
            <source>J Pak Med Assoc</source>
            <year>2018</year>
            <month>May</month>
            <volume>68</volume>
            <issue>5</issue>
            <fpage>768</fpage>
            <page-range>768-772</page-range>
            <pub-id pub-id-type="pmid">29885179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30967.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garc&#x000ed;a Mart&#x000ed;nez de Artola</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az Cuevas</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lakhwani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lecuona</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Outbreak of vancomycin-resistant <italic>enterococcus</italic> on a haematology ward: management and control.</article-title>
            <source>J Infect Prev</source>
            <year>2017</year>
            <month>May</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>149</fpage>
            <page-range>149-153</page-range>
            <pub-id pub-id-type="pmid">28989519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30967.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Musau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baumann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kolotylo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>O'Shea</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bialachowski</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Infectious disease outbreaks and increased complexity of care.</article-title>
            <source>Int Nurs Rev</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>404</fpage>
            <page-range>404-11</page-range>
            <pub-id pub-id-type="pmid">25922983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30967.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tschudin-Sutter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pargger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Widmer</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Hand hygiene in the intensive care unit.</article-title>
            <source>Crit Care Med</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>8 Suppl</issue>
            <fpage>S299</fpage>
            <page-range>S299-305</page-range>
            <pub-id pub-id-type="pmid">20647787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30967.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Linfield</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Campeau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Injean</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gregson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaldas</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kunz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Humphries</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>McKinnell</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Practical methods for effective vancomycin-resistant enterococci (VRE) surveillance: experience in a liver transplant surgical intensive care unit.</article-title>
            <source>Infect Control Hosp Epidemiol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>39</volume>
            <issue>10</issue>
            <fpage>1178</fpage>
            <page-range>1178-1182</page-range>
            <pub-id pub-id-type="pmid">30178725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30967.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Moehring</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Schwab</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Becherer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Blocker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Triplett</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Knelson</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Lokhnygina</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rutala</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Sexton</surname>
                <given-names>DJ</given-names>
              </name>
              <collab>CDC Prevention Epicenters Program</collab>
            </person-group>
            <article-title>Effectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and Clostridium difficile: a secondary analysis of a multicentre cluster randomised controlled trial with crossover design (BETR Disinfection).</article-title>
            <source>Lancet Infect Dis</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>8</issue>
            <fpage>845</fpage>
            <page-range>845-853</page-range>
            <pub-id pub-id-type="pmid">29880301</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
